Rett Syndrome: Crossing the Threshold to Clinical Translation

David M. Katz, Adrian Bird, Monica Coenraads, Steven J. Gray, Debashish U. Menon, Benjamin D. Philpot, Daniel C. Tarquinio

Research output: Contribution to journalReview article

61 Citations (Scopus)

Abstract

Lying at the intersection between neurobiology and epigenetics, Rett syndrome (RTT) has garnered intense interest in recent years, not only from a broad range of academic scientists, but also from the pharmaceutical and biotechnology industries. In addition to the critical need for treatments for this devastating disorder, optimism for developing RTT treatments derives from a unique convergence of factors, including a known monogenic cause, reversibility of symptoms in preclinical models, a strong clinical research infrastructure highlighted by an NIH-funded natural history study and well-established clinics with significant patient populations. Here, we review recent advances in understanding the biology of RTT, particularly promising preclinical findings, lessons from past clinical trials, and critical elements of trial design for rare disorders.

Original languageEnglish (US)
Pages (from-to)100-113
Number of pages14
JournalTrends in Neurosciences
Volume39
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Rett Syndrome
Neurobiology
Drug Industry
Biotechnology
Natural History
Epigenomics
Clinical Trials
Therapeutics
Research
Population

Keywords

  • Clinical trials
  • Epigenetics
  • Gene therapy
  • MECP2
  • Neurodevelopmental disorders
  • Preclinical models

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Katz, D. M., Bird, A., Coenraads, M., Gray, S. J., Menon, D. U., Philpot, B. D., & Tarquinio, D. C. (2016). Rett Syndrome: Crossing the Threshold to Clinical Translation. Trends in Neurosciences, 39(2), 100-113. https://doi.org/10.1016/j.tins.2015.12.008

Rett Syndrome : Crossing the Threshold to Clinical Translation. / Katz, David M.; Bird, Adrian; Coenraads, Monica; Gray, Steven J.; Menon, Debashish U.; Philpot, Benjamin D.; Tarquinio, Daniel C.

In: Trends in Neurosciences, Vol. 39, No. 2, 01.02.2016, p. 100-113.

Research output: Contribution to journalReview article

Katz, DM, Bird, A, Coenraads, M, Gray, SJ, Menon, DU, Philpot, BD & Tarquinio, DC 2016, 'Rett Syndrome: Crossing the Threshold to Clinical Translation', Trends in Neurosciences, vol. 39, no. 2, pp. 100-113. https://doi.org/10.1016/j.tins.2015.12.008
Katz, David M. ; Bird, Adrian ; Coenraads, Monica ; Gray, Steven J. ; Menon, Debashish U. ; Philpot, Benjamin D. ; Tarquinio, Daniel C. / Rett Syndrome : Crossing the Threshold to Clinical Translation. In: Trends in Neurosciences. 2016 ; Vol. 39, No. 2. pp. 100-113.
@article{30d410ece9ad4ed6a36e5078c7ca22bc,
title = "Rett Syndrome: Crossing the Threshold to Clinical Translation",
abstract = "Lying at the intersection between neurobiology and epigenetics, Rett syndrome (RTT) has garnered intense interest in recent years, not only from a broad range of academic scientists, but also from the pharmaceutical and biotechnology industries. In addition to the critical need for treatments for this devastating disorder, optimism for developing RTT treatments derives from a unique convergence of factors, including a known monogenic cause, reversibility of symptoms in preclinical models, a strong clinical research infrastructure highlighted by an NIH-funded natural history study and well-established clinics with significant patient populations. Here, we review recent advances in understanding the biology of RTT, particularly promising preclinical findings, lessons from past clinical trials, and critical elements of trial design for rare disorders.",
keywords = "Clinical trials, Epigenetics, Gene therapy, MECP2, Neurodevelopmental disorders, Preclinical models",
author = "Katz, {David M.} and Adrian Bird and Monica Coenraads and Gray, {Steven J.} and Menon, {Debashish U.} and Philpot, {Benjamin D.} and Tarquinio, {Daniel C.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.tins.2015.12.008",
language = "English (US)",
volume = "39",
pages = "100--113",
journal = "Trends in Neurosciences",
issn = "0378-5912",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Rett Syndrome

T2 - Crossing the Threshold to Clinical Translation

AU - Katz, David M.

AU - Bird, Adrian

AU - Coenraads, Monica

AU - Gray, Steven J.

AU - Menon, Debashish U.

AU - Philpot, Benjamin D.

AU - Tarquinio, Daniel C.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Lying at the intersection between neurobiology and epigenetics, Rett syndrome (RTT) has garnered intense interest in recent years, not only from a broad range of academic scientists, but also from the pharmaceutical and biotechnology industries. In addition to the critical need for treatments for this devastating disorder, optimism for developing RTT treatments derives from a unique convergence of factors, including a known monogenic cause, reversibility of symptoms in preclinical models, a strong clinical research infrastructure highlighted by an NIH-funded natural history study and well-established clinics with significant patient populations. Here, we review recent advances in understanding the biology of RTT, particularly promising preclinical findings, lessons from past clinical trials, and critical elements of trial design for rare disorders.

AB - Lying at the intersection between neurobiology and epigenetics, Rett syndrome (RTT) has garnered intense interest in recent years, not only from a broad range of academic scientists, but also from the pharmaceutical and biotechnology industries. In addition to the critical need for treatments for this devastating disorder, optimism for developing RTT treatments derives from a unique convergence of factors, including a known monogenic cause, reversibility of symptoms in preclinical models, a strong clinical research infrastructure highlighted by an NIH-funded natural history study and well-established clinics with significant patient populations. Here, we review recent advances in understanding the biology of RTT, particularly promising preclinical findings, lessons from past clinical trials, and critical elements of trial design for rare disorders.

KW - Clinical trials

KW - Epigenetics

KW - Gene therapy

KW - MECP2

KW - Neurodevelopmental disorders

KW - Preclinical models

UR - http://www.scopus.com/inward/record.url?scp=84959056410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959056410&partnerID=8YFLogxK

U2 - 10.1016/j.tins.2015.12.008

DO - 10.1016/j.tins.2015.12.008

M3 - Review article

C2 - 26830113

AN - SCOPUS:84959056410

VL - 39

SP - 100

EP - 113

JO - Trends in Neurosciences

JF - Trends in Neurosciences

SN - 0378-5912

IS - 2

ER -